Aripiprazole Tablet
Product Images NDC 50090-8132

12 FDA label images from A-s Medication Solutions · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 50090-8132). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure-1 (Structure 1)

Structure-1 (Structure 1)
Chemical structure of Aripiprazole, depicting the arrangement of atoms and bonds that constitute the active ingredient in this oral tablet dosage form.*
FDA Label Image

Figure1 (Figure1)

Figure1 (Figure1)
A pharmacokinetic plot titled 'Effect of Other Drugs on Aripiprazole' displaying aripiprazole fold change and 90% confidence intervals for various interacting drugs. The x-axis shows change relative to reference (without interacting drug) ranging from 0 to 3. The y-axis lists CYP3A4 inhibitor ketoconazole, CYP2D6 inhibitor quinidine, CYP3A4 inducer carbamazepine, gastric acid blocker famotidine, and other drugs valproate, lithium, and lorazepam, with PK parameters AUC and Cmax indicated. The plot illustrates how these drugs affect aripiprazole exposure measures.*
FDA Label Image

Figure2 (Figure2)

Figure2 (Figure2)
A pharmacokinetic chart titled "Effect of Other Drugs on Aripiprazole" showing dehydro-aripiprazole fold change with 90% confidence intervals. The x-axis represents change relative to a reference (without interacting drug), ranging from 0 to 3. Various inhibitors, inducers, gastric acid blockers, and other drugs are listed on the y-axis, with markers indicating their effect on AUC and Cmax values of aripiprazole.*
FDA Label Image

Figure3 (Figure3)

Figure3 (Figure3)
A chart titled 'Effect of Aripiprazole on Other Drugs' showing fold change with 90% confidence intervals for various drugs and enzymes. The x-axis represents 'Change Relative to Reference (without interacting drug)' ranging from 0.5 to 3.0. The chart compares pharmacokinetic parameters such as DMOR, AUC, Cmax, and INR for drugs including dextromethorphan, warfarin, omeprazole, lamotrigine, valproate, lithium, lorazepam, venlafaxine, O-desmethylvenlafaxine, and escitalopram.*
FDA Label Image

Figure4 (Figure4)

Figure4 (Figure4)
A forest plot titled 'Aripiprazole Fold Change and 90% CI' showing pharmacokinetic differences in special populations. The x-axis represents 'Change Relative to Reference' ranging from 0.5 to 3.0. Special populations compared include CYP2D6 metabolizer status, gender, age groups, hepatic impairment levels, and severe renal impairment, with data points and 90% confidence intervals for AUC and Cmax values.*
FDA Label Image

Figure5 (Figure5)

Figure5 (Figure5)
A chart titled 'Dehydro-Aripiprazole Fold Change and 90% CI' illustrating relative changes in AUC and Cmax by various factors including CYP2D6 metabolism status, gender, age, hepatic impairment, and renal impairment. The horizontal axis shows change relative to reference, with data points and confidence intervals for each comparison.*
FDA Label Image

Figure6 (Figure6)

Figure6 (Figure6)
A line graph showing the proportion of subjects with relapse over time in days from randomization for Aripiprazole versus placebo groups. The x-axis represents days from randomization, and the y-axis shows the proportion of subjects with relapse. The graph includes the number of subjects at risk at various time points for both treatment groups.*
FDA Label Image

Figure7 (Figure7)

Figure7 (Figure7)
A Kaplan-Meier survival curve showing the proportion of subjects with relapse over time (days from randomization) comparing Aripiprazole and placebo groups. The graph plots relapse proportion on the y-axis against days from randomization on the x-axis, with the number of subjects at risk listed below. Aripiprazole is represented by a solid blue line and placebo by a dashed red line.*
FDA Label Image

Figure8 (Figure8)

Figure8 (Figure8)
A Kaplan-Meier plot showing the proportion of subjects with relapses over 364 days from randomization. The graph compares Aripiprazole (solid blue line) and Placebo (dashed red line) groups. The x-axis represents days from randomization, and the y-axis shows the proportion with relapses. The number of subjects at risk is listed below the x-axis for each group at multiple time points.*
FDA Label Image

Figure9 (Figure9)

Figure9 (Figure9)
This line graph shows the change in YGTSS Total TIC Score from baseline over 8 weeks of treatment. It compares the least-squares mean change for three groups: Abilify Low, Abilify High, and Placebo, illustrating a greater decrease in tic scores for the Abilify High and Low groups compared to Placebo over time.*
FDA Label Image
FDA Label Image

Label Image (Lbl500908132)

Label Image (Lbl500908132)
Aripiprazole USP 2 mg oral tablets in a bottle label from A-S Medication Solutions. The label specifies each tablet contains 2 mg of aripiprazole and includes storage instructions to keep at 68 to 77 degrees Fahrenheit. The package contains 30 tablets.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.